Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solventum Corporation ( (SOLV) ) has issued an update.
Solventum Corporation completed the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. for $4.0 billion in cash on September 1, 2025. This transaction is a significant step in Solventum’s transformation plan, allowing the company to reduce debt and strengthen its balance sheet, while also updating its financial guidance for 2025 to reflect the divestiture’s impact.
The most recent analyst rating on (SOLV) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Solventum Corporation stock, see the SOLV Stock Forecast page.
Spark’s Take on SOLV Stock
According to Spark, TipRanks’ AI Analyst, SOLV is a Neutral.
Solventum Corporation’s overall stock score is driven by strong earnings call performance and strategic growth initiatives, despite challenges in profitability and leverage. Technical analysis and valuation suggest caution due to mixed signals and a relatively high P/E ratio.
To see Spark’s full report on SOLV stock, click here.
More about Solventum Corporation
Solventum Corporation operates in the healthcare industry, focusing on creating innovative solutions at the intersection of health, materials, and data science. The company aims to improve patient lives and empower healthcare professionals by delivering smarter and safer healthcare solutions.
Average Trading Volume: 924,739
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.67B
See more data about SOLV stock on TipRanks’ Stock Analysis page.